| SB1317 |
| 14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene |
| (CAS 937270-47-8) |
 |
| Description： |
SB1317 is a novel small molecule potent CDK2/JAK2/FLT3 inhibitor with IC50s of 13/73/56 nM respectively.
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and S
|
| Product No. |
KT00896 |
| Product Name |
SB1317 |
| Synonyms |
TG02; SB 1317; TG 02; SB-1317; TG-02 |
| Formal Name |
14-Methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene |
| CAS Number |
937270-47-8 |
| Molecular Formula |
C23H24N4O |
| Formula Weight |
372.46 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
(3R,4S)-Tofacitinib
(3S,4R)-Tofacitinib
(3S,4S)-Tofacitinib
AG-490
AMG 925
Amuvatinib
AST 487
AT7519
AT7519 Hydrochloride
|
|
